Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)
Sponsor: Justin Watts, MD
A PHASE1 clinical study on AML and Acute Myelogenous Leukemia, this trial is completed. The trial is conducted by Justin Watts, MD and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Aug 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Feb 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Justin Watts, MD
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .